Company Overview and News

87
Your Daily Pharma Scoop: Secondary Offering Review, Week Of June 8-15, VSTM, SRRA

2018-06-19 seekingalpha
Welcome to another week of secondary offering review. Like we have said before, secondary offerings are often a good time to enter into a stock. If a company has otherwise solid credentials but goes down on the offering, that's a good entry point, other things being constant.
GTHX CGEN KTWO VSTM ALPN CLRBZ HTGX CLRBW HTGY HTGZ HTGC CLRB SRRA

244
Your Daily Pharma Scoop: Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips

2018-06-11 seekingalpha
Aduro Biotech Inc. (ADRO) is a smallcap with a market capitalization of $533.397M. The company develops immunotherapy drugs, focuses on development of therapies that treat challenging diseases. The Berkeley, CA based company was founded as Oncologic, Inc. in 2000 and renamed to Aduro BioTech, Inc. in June 2008.
MNKD SCD IRWD CMRX TRXC K CLRBZ CLRBW OPHT ADRO FGEN JNJ IOVA LPCN CLRB PFE BMY

91
Your Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar Zooms

2018-06-11 seekingalpha
Scynexis (NASDAQ:SCYX) is a drug manufacturer focusing on infectious diseases and has $83.85M in market capitalization. The company’s lead candidate SCY-078 is on trial for treatment of multiple serious fungal infections. Some of these fungal infections like Acute Vulvovaginal Candidiasis, Invasive Candidiasis and Invasive Aspergillosis Combo are difficult to treat and can turn into life-threatening conditions.
REGN MYO GSK ZTS CLRB GSK CLRBZ PRPO CLRBW PTI SCYX

17
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma

2018-06-06 globenewswire
MADISON, Wis., June 06, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

18
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

2018-05-09 globenewswire
MADISON, Wis., May 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

17
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broad Range of Tumor Cells

2018-04-16 globenewswire
MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today the presentation of a late breaker poster entitled “Phospholipid drug conjugates (PDC™) show specificity for a broad range of tumor cells and provides a novel approach for targeted or precision therapy” at the American Association for Cancer Research (AACR) Annual Meeting underway in Chicago.
CLRB CLRBZ CLRBW

17
Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar’s CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting

2018-04-16 globenewswire
MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces the presentation of CLR 131 preclinical data in a poster discussion entitled “Therapeutic Combination of Radiolabeled CLR1404 with External Beam Radiation in Head and Neck Cancer Murine Xenograft Models” at the American Association for Cancer Research (AACR) Annual Meeting underway in Chicago.
CLRB CLRBZ CLRBW

64
Cerecor Appoints Simon Pedder to its Board of Directors

2018-04-09 marketwired
BALTIMORE, MD--(Marketwired - April 09, 2018) - Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors.
CERC ATNX CLRB CLRBZ CLRBW

54
Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer

2018-04-04 globenewswire
MADISON, Wis., April 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announces the appointment of Brian M. Posner as chief financial officer, effective as of April 1, 2018.
LGNZZ LGNYZ LGND LGNXZ CLRB LGNDZ CLRBZ CLRBW OPTT

17
Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma

2018-04-03 globenewswire
MADISON, Wis., April 03, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. P150207US03, entitled “Alkylphosphocholine analogs for multiple myeloma imaging and therapy.
CLRB CLRBZ CLRBW

17
Cellectar Biosciences' (CLRB) CEO Jim Caruso on Q4 2017 Results - Earnings Call Transcript

2018-03-22 seekingalpha
Welcome to the Cellectar Biosciences 2017 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we’ll hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded March 22, 2018.
CLRB CLRBZ CLRBW

43
Cellectar Biosciences' (CLRB) CEO James Caruso on Q4 2017 Results - Earnings Call Transcript

2018-03-22 seekingalpha
Welcome to the Cellectar Biosciences 2017 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we’ll hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded March 22, 2018.
ONTX CLRB CLRBZ ONTXW CLRBW

17
Cellectar Reports 2017 Financial Results and Provides a Corporate Update

2018-03-21 globenewswire
MADISON, Wis., March 21, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today reported financial results for 2017 and provided a corporate update.
CLRB CLRBZ CLRBW

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 15117F120